@article{oai:hirosaki.repo.nii.ac.jp:00005786,
 author = {Kudo, Naomi and Abe, Takahisa and Midorikawa, Shin and Matsubara, Atsushi},
 issue = {1},
 journal = {弘前医学},
 month = {Nov},
 note = {In recent years, anti-programmed cell death 1（ PD-1） antibody has been approved for recurrent/metastatic head and neck cancer and was reported by the phase 3 study ChackMate 141 to improve the overall survival rate of patients with recurrent/metastatic head and neck squamous cell carcinoma. With the increasing number of cases treated with anti-PD-1 antibody, the synergic interaction between cancer immunotherapy and chemotherapy has been gathering attention. Some reported that administration of chemotherapy after immunotherapy was remarkably effective for progressive non-small cell lung cancer. We examined two notable cases of recurrent/metastatic head and neck cancer in which the subsequent administration of chemotherapy after immunotherapy was markedly effective. The two cases included maxillary sinus cancer and laryngeal cancer that were treated with radiotherapy and chemotherapy as first-line treatment. Both cases developed recurrent/metastatic lesion that were treated with anti-PD-1 antibody. However, the lesions increased in size after immunotherapy. Therefore, subsequent chemotherapy with cetuximab and paclitaxel was considered and showed marked reduction of size of the recurrent/metastatic lesions. The two cases suggested that administration of salvage chemotherapy after immunotherapy is promising for recurrent/ metastatic head and neck cancer.},
 pages = {72--76},
 title = {Remarkable effects of salvage chemotherapy with cetuximab and paclitaxel after cancer immunotherapy in two cases of recurrent/metastatic head and neck cancer},
 volume = {70},
 year = {2019}
}